The most important number for a wearable robot isn't its torque or its battery life. It's the weight a patient is willing to carry for an hour. At 4.5 kilograms, Hurotics' H-Medi exosuit is about as heavy as a small bag of rice, a fact that has let it walk out of the lab and into the daily routines of major Korean hospitals [Founderland, October 2026].
Founded in 2022 by Chung-Ang University professor Lee Gi-wook, Hurotics is betting that the future of gait rehabilitation is soft, made of fabric and cables, not metal and rigid frames. In October 2026, that bet attracted a ₩25 billion (approximately $18.6 million) Series A round from a consortium that reads like a who's who of Korean industry: Atinum Investment led, with strategic checks from Daewoong Pharmaceutical, NAVER, and Lotte [The Seoul Economic Daily, October 2026]. The money will fund an expansion that's already begun, with the suit landing at the University of Illinois Chicago for research this past June [dealroom.co].
The Wedge Is a Weighted Vest
The company's technical wedge is straightforward: make it light enough to wear, and fast enough to put on. Traditional exoskeletons for rehabilitation are often bulky, expensive machines that require technician assistance. H-Medi uses textiles and flexible materials, which the company says allows patients with joint stiffness to wear it comfortably for extended periods and permits a donning time of less than two minutes [donga.com, December 2025].
The suit is a Class 2 medical device in South Korea, intended for clinical gait rehabilitation, assisting with muscle reconstruction and joint motion recovery, often for stroke patients [Exoskeleton Report]. The "soft robot" approach uses cable-driven actuators, a method that trades some raw lifting power for a form factor that looks more like high-tech athletic wear than industrial machinery.
A Professor's Path to Commercialization
The company is a classic academic spinout, with founder Lee Gi-wook's research in mechanical engineering at Chung-Ang University providing the foundation [PERPLEXITY SONAR PRO BRIEF]. His background includes a postdoctoral fellowship at Harvard University, anchoring the venture in biomechanics research [Crunchbase]. The transition from lab to clinic appears to have been swift; Hurotics commercialized H-Medi in September 2025 and within a year had it adopted by three major Seoul hospitals: Sinchon Severance Hospital, Chung-Ang University Hospital, and Korea University Hospital [Asiae, October 2026].
The recent funding round, which brings cumulative investment to over ₩33.5 billion (estimated $24.8 million), signals a shift from proving the technology to scaling its distribution and next-generation development [The Seoul Economic Daily, October 2026]. The investor mix is notable:
- Strategic Pharma: Daewoong Pharmaceutical's participation hints at a natural alignment with rehabilitation medicine and future clinical pathways.
- Tech and Retail Giants: NAVER and Lotte bring potential channels for future consumer-facing products and digital integration.
- Financial Backing: A cohort of Korean venture firms and banks, including Stonebridge Ventures and Industrial Bank of Korea, provides the growth capital.
The company is actively hiring across hardware, firmware, and production roles, suggesting the capital is being deployed to build out its operational muscle for manufacturing and quality control [HUROTICS].
The Road from Clinic to Home
Traction in prestigious hospitals is a strong start, but the real market test is what comes next. The company is already developing H-Care, a product intended for everyday walking assistance rather than clinical rehabilitation [PERPLEXITY SONAR PRO BRIEF]. This represents the classic medtech arc: prove efficacy and safety in a controlled clinical setting, then move toward broader adoption. The export of H-Medi to the University of Illinois Chicago is a critical first step in this international and clinical validation process [dealroom.co].
The risks here are well-worn but formidable. Regulatory pathways in markets like the US or EU are lengthy and expensive. While the soft design is an advantage for comfort, it may face limitations in the level of assistive force it can provide compared to rigid exoskeletons for patients with severe mobility impairments. Furthermore, the business model of selling capital equipment to hospitals is a known grind, with long sales cycles and intense competition on clinical evidence.
Hurotics' answer seems to be a focus on the user experience metrics that matter most in a clinical setting: setup time and patient compliance. A therapist can get a patient into the suit in two minutes, not twenty. A patient can tolerate it for a full session because it doesn't feel like a machine. These are the unit economics of rehabilitation,minutes saved per session, sessions completed per week,that ultimately drive hospital purchasing decisions.
The Next Twelve Months
The immediate roadmap is clear. The Series A capital must fund the pursuit of overseas regulatory approvals, a process The Seoul Economic Daily noted was a priority [The Seoul Economic Daily, October 2026]. Building on the research partnership in Chicago will be key to generating the peer-reviewed data that opens doors in Western healthcare systems. Concurrently, scaling production to meet demand from its initial hospital customers and potentially from new markets will test the operational hires now being made.
A simple calculation illustrates the scale of the opportunity. Assume a mid-sized rehabilitation clinic sees 20 stroke patients a day for gait therapy. If H-Medi can increase productive therapy time by just 15 minutes per patient by simplifying setup and improving comfort, that's five extra hours of clinician capacity per day. At typical outpatient therapy rates, that extra capacity could justify the hardware cost in a matter of months. The real product isn't the suit; it's the recovered time.
For now, Hurotics must prove it can do more than win pilot programs. It must become the default piece of equipment a hospital buys when it decides to modernize its gait lab, displacing the clunkier, more intimidating machines that have defined the category for years. The bet is that in rehabilitation, gentle force applied through fabric will beat brute strength delivered through steel.
Sources
- [Asiae, October 2026] Hyurotics Raises 25 Billion Won in Series A Funding | https://www.asiae.co.kr/en/article/2026101508245845605
- [Crunchbase] Giuk Lee - Founder & CEO @ Hurotics - Crunchbase Person Profile | https://www.crunchbase.com/person/giuk-lee
- [dealroom.co] Hurotics company profile | https://tracxn.com/d/companies/hurotics/__ywKwwGB4TFRnMp2z6SiDxZWcgSj2NDIaimDpmpnQrws
- [donga.com, December 2025] Hurotics: Pioneering Gait Rehab with "Exosuits" as Light and Wearable as Clothing | https://www.donga.com/en/article/all/20251217/6015670/1
- [Exoskeleton Report] H-Medi - Exoskeleton Report | https://exoskeletonreport.com/product/h-medi/
- [Founderland, October 2026] HUROTICS raises $18.6M for medical exosuit technology | https://www.founderland.ai/articles/hurotics-raises-186m-for-medical-exosuit-technology-mv9qve23
- [HUROTICS] HUROTICS company website | https://www.hurotics.com/en/
- [PERPLEXITY SONAR PRO BRIEF] Hurotics, research brief
- [The Seoul Economic Daily, October 2026] Wearable Robot Maker Hurotics Raises 25 Billion Won in … | https://en.sedaily.com/technology/2026/10/15/wearable-robot-maker-hurotics-raises-25-billion-won-in